@article{b1cb1c03666e447493bef0c3a6a0afe4,
title = "Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening",
abstract = "Covalent probes can display unmatched potency, selectivity, and duration of action; however, their discovery is challenging. In principle, fragments that can irreversibly bind their target can overcome the low affinity that limits reversible fragment screening, but such electrophilic fragments were considered nonselective and were rarely screened. We hypothesized that mild electrophiles might overcome the selectivity challenge and constructed a library of 993 mildly electrophilic fragments. We characterized this library by a new high-throughput thiol-reactivity assay and screened them against 10 cysteine-containing proteins. Highly reactive and promiscuous fragments were rare and could be easily eliminated. In contrast, we found hits for most targets. Combining our approach with high-throughput crystallography allowed rapid progression to potent and selective probes for two enzymes, the deubiquitinase OTUB2 and the pyrophosphatase NUDT7. No inhibitors were previously known for either. This study highlights the potential of electrophile-fragment screening as a practical and efficient tool for covalent-ligand discovery.",
author = "Efrat Resnick and Anthony Bradley and Jinrui Gan and Alice Douangamath and Tobias Krojer and Ritika Sethi and Geurink, {Paul P.} and Anthony Aimon and Gabriel Amitai and Dom Bellini and James Bennett and Michael Fairhead and Oleg Fedorov and Ronen Gabizon and Jin Gan and Jingxu Gu and Alexander Plotnikov and Nava Reznik and Ruda, {Gian Filippo} and Laura Diaz-Saez and Straub, {Verena M.} and Tamas Szommer and Srikannathasan Velupillai and Daniel Zaidman and Yanling Zhang and Coker, {Alun R.} and Dowson, {Christopher G.} and Barr, {Haim M.} and Chu Wang and Huber, {Kilian V. M.} and Brennan, {Paul E.} and Huib Ovaa and {von Delft}, Frank and Nir London",
note = "N.L. is the incumbent of the Alan and Laraine Fischer Career Development Chair. N.L. wishes to acknowledge funding from the Israel Science Foundation (Grant No. 1097/16), The Rising Tide Foundation, The Israel Cancer Research Foundation, and the Israeli Ministry of Science and Technology (Grant No. 3-14763). This work was supported by the Dutch Organization for Scientific Research NWO (VICI grant 724.013.002 to H.O.) We thank Yves Leestemaker for assistance with the DUB ABPP assays. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, the Canada Foundation for Innovation, the Eshelman Institute 22 for Innovation, Genome Canada through Ontario Genomics Institute (OGI-055)], the Innovative Medicines Initiative (EU/EFPIA) (ULTRA-DD Grant No. 115766), Janssen, Merck KGaA (Darmstadt, Germany), MSD, Novartis Pharma AG, the Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, Sao Paulo Research Foundation-FAPESP, Takeda, and Wellcome (106169/Z/14/Z). Supported by a research grant from the Nancy and Stephen Grand Israel National Center for Personalized Medicine. We thank Ilana Berlin for providing the GFP-OTUB2 plasmids. We thank Prof. Deborah Fass for the generous gift of QSOX1 protein.",
year = "2019",
month = jun,
day = "5",
doi = "10.1021/jacs.9b02822",
language = "الإنجليزيّة",
volume = "141",
pages = "8951--8968",
journal = "Journal of the American Chemical Society",
issn = "0002-7863",
publisher = "American Chemical Society",
number = "22",
}